Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011959 · ClinicalTrials.gov registry record · Phase 1
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
A Phase 1 study of Rheumatoid Arthritis, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT01011959: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by Regeneron Pharmaceuticals.
NCT01011959 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 60 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011959, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.
Conditions Studied
Interventions
- BIOLOGICAL REGN88
Study Locations (20)
Florida
- - Boca Raton
- - Clearwater
- - Daytona Beach
- - Delray Beach
- - Palm Harbor
Missouri
- - Kalamzaoo
- - St Louis
Ohio
- - Cincinnati
- - Toledo
South Carolina
- - Greenville
- - Orangeburg
California
- - Santa Maria
Idaho
- - Idaho Falls
Massachusetts
- - Worcester
Michigan
- - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
What the finished NCT01011959 record still lists
NCT01011959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which REGN88 is the first listed.
NCT01011959 names 20 study sites across 13 states, led by Florida, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT01011959 about?
NCT01011959 is a clinical study titled "A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects". This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.
What is the current status of trial NCT01011959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-12. Estimated completion is 2009-08.
What conditions does trial NCT01011959 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01011959?
The interventions under investigation include: REGN88 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01011959?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01011959 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01011959's enrollment target sits among peer trials
60 135th of 197 higher than 63 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia